Company biOasis Technologies Inc Toronto S.E.
Equities
BTI
CA09064N1033
Biotechnology & Medical Research
Business Summary
Sales per Business
CAD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Diagnosis and Treatment of Neurological Diseases and Disorders
100.0
%
| 4 | 100.0 % | 0 | 100.0 % | -99.07% |
Sales per region
CAD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Canada
100.0
%
| 4 | 100.0 % | 0 | 100.0 % | -99.07% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Deborah Rathjen
CEO | Chief Executive Officer | - | 17-09-20 |
Dave Jenkins
DFI | Director of Finance/CFO | - | 21-06-30 |
Mei Mei Tian
CTO | Chief Tech/Sci/R&D Officer | - | 11-12-31 |
Graeme Dick
IRC | Investor Relations Contact | - | 11-10-31 |
Christopher Lowe
SEC | Corporate Secretary | 56 | 17-10-02 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
John Hemeon
BRD | Director/Board Member | 59 | - |
David Wurzer
BRD | Director/Board Member | 65 | 18-07-26 |
Deborah Rathjen
CEO | Chief Executive Officer | - | 17-09-20 |
Director/Board Member | 63 | 18-05-31 | |
John E. Curran
BRD | Director/Board Member | - | 18-07-26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 79,414,015 | 77,784,778 ( 97.95 %) | 0 | 97.95 % |
Company contact information
![address biOasis Technologies Inc(BTI)](https://cdn.zonebourse.com/static/address/2941086.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+16.59% | 44.87B | |
-10.62% | 37.8B | |
+40.49% | 37.61B | |
+29.92% | 31.32B | |
-9.78% | 27.4B | |
+12.34% | 26.32B | |
+41.53% | 14.07B | |
+31.49% | 12.5B | |
-7.40% | 11.23B |